Modern rheumatology · 2026
Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: Long-term efficacy and safety through 5 years in the SELECT-EARLY study.
СтатьяРандомизированное исследованиеКлиническое исследование III фазыМногоцентровое исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Takeuchi Tsutomu, van Vollenhoven Ronald, Ueki Yukitaka, Atsumi Tatsuya, Meerwein Sebastian, Bu Xianwei, Hirata Kazuya, Strand Vibeke
Аннотация
OBJECTIVE: To evaluate the long-term (5-year) efficacy and safety of upadacitinib monotherapy compared with methotrexate (MTX) monotherapy in Japanese patients with rheumatoid arthritis who were included in the Phase 3 SELECT-EARLY study.
METHODS: Japanese patients were randomised 2:1:1:1 to upadacitinib 7.5, 15, or 30 mg daily, or MTX 7.5 mg/week (titrated to ≤15 mg/week). Efficacy assessments through Week 260 are reported as observed for patients receiving continuous upadacitinib or MTX, and by randomised group using non-responder imputation. Treatment-emergent adverse events were collected over 5 years and reported as events per 100 patient-years.
RESULTS: Of the 138 Japanese patients treated, 123 (89%) completed Week 48, and 121 (88%) entered the long-term extension on the study drug. Patients receiving upadacitinib had better overall long-term efficacy outcomes compared with patients receiving MTX. Similarly, treatment with upadacitinib resulted in numerically greater inhibition of structural joint progression through 5 years, relative to MTX. Higher treatment-emergent adverse event rates were observed in the 30 mg upadacitinib group compared with all other treatment groups, and no new safety signals were identified overall.
CONCLUSION: This subanalysis of the SELECT-EARLY Japanese population corroborates findings from the global study population on the long-term clinical efficacy and safety of upadacitinib.
METHODS: Japanese patients were randomised 2:1:1:1 to upadacitinib 7.5, 15, or 30 mg daily, or MTX 7.5 mg/week (titrated to ≤15 mg/week). Efficacy assessments through Week 260 are reported as observed for patients receiving continuous upadacitinib or MTX, and by randomised group using non-responder imputation. Treatment-emergent adverse events were collected over 5 years and reported as events per 100 patient-years.
RESULTS: Of the 138 Japanese patients treated, 123 (89%) completed Week 48, and 121 (88%) entered the long-term extension on the study drug. Patients receiving upadacitinib had better overall long-term efficacy outcomes compared with patients receiving MTX. Similarly, treatment with upadacitinib resulted in numerically greater inhibition of structural joint progression through 5 years, relative to MTX. Higher treatment-emergent adverse event rates were observed in the 30 mg upadacitinib group compared with all other treatment groups, and no new safety signals were identified overall.
CONCLUSION: This subanalysis of the SELECT-EARLY Japanese population corroborates findings from the global study population on the long-term clinical efficacy and safety of upadacitinib.